Securities code: Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) securities abbreviation: Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) Announcement No.: 2022007
Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513)
Announcement on applying for comprehensive credit line from banks and other financial institutions
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law. Important content tips:
In 2022, the company and its wholly-owned subsidiaries intend to apply for a comprehensive credit line of no more than RMB 500 million from banks and other financial institutions.
This matter falls within the decision-making authority of the board of directors and does not need to be submitted to the general meeting of shareholders for deliberation.
Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) (hereinafter referred to as “the company”) held the second meeting of the third board of directors on March 28, 2022, deliberated and adopted the proposal on applying for comprehensive credit line from banks and other financial institutions. Relevant matters are hereby announced as follows:
In order to meet the capital needs of the company’s operation and development, enhance the company’s capital strength, strengthen cooperation with financial institutions, maintain good cooperative relations, and increase the company’s credit in financial institutions, the company and its wholly-owned subsidiaries intend to apply to banks and other financial institutions for a comprehensive credit line of no more than RMB 500 million. The credit business includes but is not limited to loans, acceptance bills, trade financing, letter of guarantee, etc. The specific business type, line and term of credit shall be subject to the final approval of the financial institution.
The above credit line is not equal to the actual financing amount of the company. The actual financing amount is within the total credit line, subject to the actual financing amount of the company, its wholly-owned subsidiaries and financial institutions. The specific financing amount and variety will be reasonably determined according to the actual needs of the company’s business development.
If the company needs to provide corresponding guarantee or other forms of guarantee in the application for credit line, pledge or other credit investigation measures, it can be provided in the above-mentioned financial institutions. The validity period of this application for comprehensive credit is 18 months from the date of deliberation and approval by the board of directors.
In order to improve the financing efficiency, the board of directors of the company agrees to authorize the chairman of the company to sign the legal documents related to this credit on behalf of the company within the above comprehensive credit line (including but not limited to signing the credit, loan contract and other legal documents).
It is hereby announced.
Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) board of directors
March 29, 2022
